Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 657-674

  Ko, Seung Sang ^a,b   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Bisphosphonate; Breast cancer; Lasofoxifene; Osteoporosis; Raloxifene; Selective estrogen receptor modulator

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; CLOMIFENE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; BREAST DISEASE; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CATARACT; CEREBROVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FRACTURE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HIP FRACTURE; HUMAN; INFERTILITY; JAW OSTEONECROSIS; LUNG EMBOLISM; MULTICENTER STUDY (TOPIC); OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASOMOTOR DISORDER; VASOMOTOR SYMPTOM; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RALOXIFENE; RISK; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79951593577     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.557360     Document Type: Article

References (100)

1. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002;23:279-302 (Pubitemid 34651948)
2. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass.; Available from: advocacy/prevalence/index.htm [Cited 13 Augest 2010]
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
4. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92
5. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82
6. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29 (Pubitemid 36210865)
7. Jordan VC. SERMs: meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007;99:350-6 (Pubitemid 47078725)
8. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007;7:46-53 (Pubitemid 46020846)
9. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila Pa) 2010;3:696-706
10. Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58
11. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001;61:5683-7 (Pubitemid 32769076)
12. Jensen EV, Greene GL, Closs LE, et al. Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res 1982;38:1-40
13. Bryant HU. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev Endocr Metab Disord 2001;2:129-38 (Pubitemid 33643899)
14. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999;103:401-6 (Pubitemid 29069990)
15. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-70 (Pubitemid 27089735)
16. Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999;140:5828-40 (Pubitemid 30645372)
17. Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas 2007;56:38-44 (Pubitemid 44894788)
18. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45 (Pubitemid 29384151)
19. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97 (Pubitemid 29275701)
20. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17 (Pubitemid 34879503)
21. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61 (Pubitemid 39654569)
22. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24 (Pubitemid 41243540)
23. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
24. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
25. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51
26. Recker RR, Kendler D, Recknor CP, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007;40:843-51 (Pubitemid 46386535)
27. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125-34 (Pubitemid 32193616)
28. Barrett-Connor E, Wenger NK, Grady D, et al. Coronary heart disease in women, randomized clinical trials, HERS and RUTH. Maturitas 1998;31:1-7 (Pubitemid 29050884)
29. Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000;85:2197-202 (Pubitemid 32269244)
30. Weinstein RS, Parfitt AM, Marcus R, et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003;14:814-22 (Pubitemid 37462131)
31. Neele SJ, Evertz R, De Valk-De Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603 (Pubitemid 34270498)
32. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44 (Pubitemid 36870506)
33. Briot K, Tremollieres F, Thomas T, Roux C. How long should patients take medications for postmenopausal osteoporosis? Joint Bone Spine 2007;74:24-31
34. Kung AW, Chao HT, Huang KE, et al. Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 2003;88:3130-6 (Pubitemid 36877483)
35. Morii H, Ohashi Y, Taketani Y, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 2003;14:793-800 (Pubitemid 37462128)
36. Byrjalsen I, Leeming DJ, Qvist P, et al. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008;19:339-48 (Pubitemid 351199183)
37. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-3 (Pubitemid 34522401)
38. Qu Y, Wong M, Thiebaud D, Stock JL. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. Curr Med Res Opin 2005;21:1955-9 (Pubitemid 41803106)
39. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293-300 (Pubitemid 37107463)
40. Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int 2002;13:907-13 (Pubitemid 35364793)
41. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32 (Pubitemid 37222378)
42. Brown JP, Fortier M, Frame H, et al. Canadian consensus conference on osteoporosis, 2006 update. J Obstet Gynaecol Can 2006;28:S95-112
43. Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-14 (Pubitemid 33150991)
44. Gradishar W, Glusman J, Lu Y, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000;88:2047-53 (Pubitemid 30233206)
45. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22 (Pubitemid 34494352)
46. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-6 (Pubitemid 32060890)
47. Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10:961-6 (Pubitemid 32844904)
48. Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: breast cancer. J Clin Oncol 2005;23:357-67 (Pubitemid 46209965)
49. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46
50. Wenger NK, Barrett-Connor E, Collins P, et al. Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol 2002;90:1204-10 (Pubitemid 35346876)
51. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17:1939-55 (Pubitemid 29269268)
52. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328-43 (Pubitemid 34831530)
53. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, DC; 2010
54. World Health Organization. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003;921:1-164
55. Stevenson JC. Hormone replacement therapy and cardiovascular disease revisited. Menopause Int 2009;15:55-7
56. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009;9:77-85
57. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188-94
58. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967-75
59. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
60. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75
61. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010;102:1099-105
62. Gnant M. Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 2009;9:824-33
63. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010;28:3582-90
64. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010;28:3577-81
65. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 2010;102:799-802
66. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008;19:2007-11
67. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006;8:R13
68. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47:740-6 (Pubitemid 351878444)
69. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421-8
70. Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30:1807-13
71. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007;8:229-39 (Pubitemid 47524868)
72. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62 (Pubitemid 41672231)
73. Vastag B. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs. J Natl Cancer Inst 2006;98:733-5
74. Morii H. Safety profile of raloxifene. Clin Calcium 2004;14:100-4
75. Gelber RP, Seto TB. Patient ethnicity and use of venous thromboembolism prophylaxis. Int J Qual Health Care 2006;18:23-9 (Pubitemid 43179813)
76. Pasion EG, Sivananthan SK, Kung AW, et al. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 2007;25:105-13 (Pubitemid 46328666)
77. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 2004;19:1270-5 (Pubitemid 41094367)
78. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213 (Pubitemid 351665507)
79. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
80. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809 (Pubitemid 350044800)
81. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61 (Pubitemid 46780635)
82. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301 (Pubitemid 40463979)
83. Grey A, Cundy T. Bisphosphonates and osteonecrosis of the jaw [author reply 92]. Ann Intern Med 2006;145:791 (Pubitemid 351650366)
84. Watts NB, Harris ST, McClung MR, et al. Bisphosphonates and osteonecrosis of the jaw [author reply 92]. Ann Intern Med 2006;145:791-2 (Pubitemid 351650367)
85. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23 (Pubitemid 46343586)
86. Michalska D, Stepan JJ, Basson BR, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006;91:870-7 (Pubitemid 43357752)
87. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52 (Pubitemid 41368577)
88. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 2004;147:783-9 (Pubitemid 38880982)
89. Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest 2008;38:117-25 (Pubitemid 351143411)
90. Stefanick ML. Risk-benefit profiles of raloxifene for women. N Engl J Med 2006;355:190-2 (Pubitemid 44050402)
91. Pines A. Postmenopausal hormone therapy: the way ahead. Maturitas 2007;57:3-5 (Pubitemid 46602880)
92. Jordan VC. Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. Cancer Invest 1988;6:589-95 (Pubitemid 19042665)
93. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96
94. Pinkerton JV, Stovall DW. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women. Expert Opin Investig Drugs 2010;19:1613-21
95. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708
96. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
97. Mueck AO, Lippert C, Seeger H, Wallwiener D. Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch Gynecol Obstet 2003;267:139-44 (Pubitemid 36717878)
98. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-59 (Pubitemid 41782284)
99. Jordan VC, Lewis-Wambi JS, Patel RR, et al. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast 2009;18(Suppl 3):S10-17
100. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)